{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Faour A"],"funding":["Novartis Pharmaceuticals Corporation"],"pagination":["e0259148"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8547635"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(10)"],"pubmed_abstract":["<h4>Background</h4>The safety and efficacy profile of bivalirudin has not been examined in a randomised controlled trial of patients undergoing rescue PCI.<h4>Objectives</h4>We conducted an open-label, multi-centre, randomised controlled trial to compare bivalirudin with heparin ± glycoprotein IIb/IIIa inhibitors (GPIs) in patients undergoing rescue PCI.<h4>Methods</h4>Between 2010-2015, we randomly assigned 83 patients undergoing rescue PCI to bivalirudin (n = 42) or heparin ± GPIs (n = 41). The primary safety endpoint was any ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) bleeding at 90 days. The primary efficacy endpoint was infarct size measured by peak troponin levels as a multiple of the local upper reference limit (Tn/URL). Secondary endpoints included peripr"],"journal":["PloS one"],"pubmed_title":["Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention."],"pmcid":["PMC8547635"],"funding_grant_id":["The Medicines Company"],"pubmed_authors":["Juergens CP","Lo S","Collins N","Williams T","Khan A","Chew DP","Walters DL","French JK","Faour A"],"additional_accession":[]},"is_claimable":false,"name":"Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention.","description":"<h4>Background</h4>The safety and efficacy profile of bivalirudin has not been examined in a randomised controlled trial of patients undergoing rescue PCI.<h4>Objectives</h4>We conducted an open-label, multi-centre, randomised controlled trial to compare bivalirudin with heparin ± glycoprotein IIb/IIIa inhibitors (GPIs) in patients undergoing rescue PCI.<h4>Methods</h4>Between 2010-2015, we randomly assigned 83 patients undergoing rescue PCI to bivalirudin (n = 42) or heparin ± GPIs (n = 41). The primary safety endpoint was any ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) bleeding at 90 days. The primary efficacy endpoint was infarct size measured by peak troponin levels as a multiple of the local upper reference limit (Tn/URL). Secondary endpoints included peripr","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T22:43:13.27Z","creation":"2025-04-04T22:43:13.27Z"},"accession":"S-EPMC8547635","cross_references":{"pubmed":["34699549"],"doi":["10.1371/journal.pone.0259148"]}}